Immuron (IMRN) has released an update.
Immuron Limited’s CEO, Steven Lydeamore, is set to present at the Sharewise conference on July 9, 2024, discussing the company’s sales growth for Travelan, their clinical program for Clostridioides difficile, and forthcoming milestones. Interested parties can attend the presentation through a live Zoom webinar, with a Q&A session to follow. Immuron, an Australian biopharmaceutical company, specializes in the development and commercialization of oral antibodies for infectious diseases, with products like Travelan offering protection against travelers’ diarrhea.
For further insights into IMRN stock, check out TipRanks’ Stock Analysis page.
